Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.

Neurogene Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE) and Lyell Immunopharma (LYEL) with ...

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and M...

Market Cap	$463.79M	P/E Ratio	N/A
52W High	$37.27	52W Low	$14.65
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-0.6%	52W Position	74.6%
Overall Score	55	Value Score	--
Quality Score	21	Technical Score	90

EPS Current Est	$-5.63	EPS Next Est	$-5.49
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NGNE	$31.53	+2.40%	308.96K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NGNE	$31.53	+2.4%	308.96K
3
4
5
6

NGNE

NGNE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Neurogene Inc. Data in Excel

Get Neurogene Inc. Data in Excel